A cost‐effectiveness analysis of real‐world treatment for elderly patients with multiple myeloma using a full disease model

Blommestein, Hedwig M.; Verelst, S.; Groot, Saskia de; Huijgens, Peter C.; Sonneveld, Pieter; Groot, Carin A. Uyl–de

doi:10.1111/ejh.12571

Cited by 34 publications

(37 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, bortezomib‐based interventions were considered cost‐effective in most included studies, with incremental ratios ranging from dominant to $94 047/LY and $141 070/QALY. Finally, the only economic evaluation based on real‐world data showed that the thalidomide, lenalidomide, bortezomib sequence would be the most cost‐effective for elderly patients with MM …”

Section: Resultsmentioning

confidence: 99%

“…After reviewing the titles and abstracts, 16 articles were selected for full-text examination. Of these, eight economic studies [14][15][16][17][18][19][20][21] fully met the eligibility criteria and were included in this systematic review. Excluded studies and reasons for their exclusion are detailed in Appendix S2.…”

Section: Search Resultsmentioning

confidence: 99%

“…Finally, the only economic evaluation based on real-world data showed that the thalidomide, lenalidomide, bortezomib sequence would be the most cost-effective for elderly patients with MM. 21…”

Section: Results Of Economic Analysesmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?

2016

View full text Add to dashboard Cite

Summary What is known and objective Given the increasing healthcare costs and the recent introduction of novel agents in the treatment for multiple myeloma (MM), an incurable haematologic malignancy, more efficient use of existing resources is fundamental. The objective of this study was to systematically review economic evaluations of the use of novel agents in MM and assess their reporting quality. Methods A literature search was performed in PubMed/Medline, Latin American and Caribbean Health Sciences Literature, Cost‐Effectiveness Analysis Registry and the National Health Services Economic Evaluation Database for economic evaluations up to June 2015. The search strategy included Medical Subject Headings terms or text words related to MM, economic evaluations and drugs. Full economic evaluations of bortezomib, thalidomide or lenalidomide in patients with MM that were published in English, Portuguese or Spanish were included. Two independent authors performed study selection, data extraction and quality assessment using 24 items from the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Results and discussion Of the 132 potentially relevant records identified, eight satisfied the inclusion criteria. Most studies were cost‐effectiveness analyses combined with cost‐utility analyses (n = 6) from the public payer perspective (n = 4) and were performed in Europe (n = 6) on patients with refractory or relapsed MM (n = 5). All studies were based on economic models, with four of them using discrete event simulation. We found bortezomib‐based therapies to be one of the more commonly selected treatment strategies for comparison (n = 7). Overall, the intervention was more effective and costlier than the alternative strategy (average of $54 630 per life year; $68 261 per quality‐adjusted life year–QALY). The CHEERS’ total score was 14·6 (SD = 2·6) with the most frequent problems being the lack of precision measures for all model parameters, no evaluation of heterogeneity of the results by subgroup analyses and no description of the role the funder in the identification, design, conduct and reporting of the analysis. What is new and conclusion Most analyses of the novel therapeutic agents determined that they were cost‐effective in MM at a threshold of up to $100 000/QALY. Nevertheless, the poor reporting quality of the economic studies requires improvement to ensure greater transparency.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Search Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?

2016

View full text Add to dashboard Cite

show abstract

“…Table 1 provides an overview of the mission and goals of the registries in which we are involved. All registries ensure transparency to the public through presentations and publications [7][8][9][10][11][12][13][14]. However, only the melanoma registry (Dutch Melanoma Treatment Registry [DMTR]) fortnightly provides clinicians with online benchmarked feedback regarding a predefined set of quality indicators developed by the professional organization.…”

Section: Mission and Goals ("The Why")mentioning

confidence: 99%

“…An intervention-based registry addresses research questions regarding appropriate use, effectiveness, cost-effectiveness, and safety. Disease-based registries provide additional information and facilitate studying the full disease course including (sequential) treatment pathways [11]. Furthermore, such a registry provides information on the number of untreated patients and whether these patients would have been eligible for treatment.…”

Section: Type and Content ("The What")mentioning

confidence: 99%

Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma

et al. 2021

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Although the number of treatments for elderly patients with non-transplant-eligible (NTE) multiple myeloma (MM) has increased substantially, evidence is lacking on the clinical effectiveness and cost-effectiveness of novel treatment sequences. OBJECTIVE To determine the optimal sequence of treatment for patients with NTE MM from the perspective of the patient, physician, and society. DESIGN, SETTING, AND PARTICIPANTS Using data from a Dutch observational registry, this economic evaluation combined evidence from network meta-analyses in a patient-level simulation model and modeled time-to-event and types of events from a hospital perspective with a lifetime horizon. Data analysis was performed from June 2019 to September 2020. INTERVENTIONS Thirty treatment sequences, including up to 3 lines of therapy, were compared with bortezomib-melphalan-prednisone (VMP)-lenalidomide-dexamethasone (LenDex)-pomalidomide-dexamethasone (PomDex). MAIN OUTCOMES AND MEASURESThe primary outcomes of the model were overall survival (OS), quality-adjusted life-years (QALYs), costs, and cost-effectiveness.

show abstract

A cost‐effectiveness analysis of real‐world treatment for elderly patients with multiple myeloma using a full disease model

Abstract: Our patient-level model enabled to study the effects and costs of entire treatment sequences and to compare real-world treatment patterns over time. Increased utilisation of novel agents improved survival and increased costs for real-world patients with MM in the Netherlands.

Cited by 34 publications

References 38 publications

Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?

Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?

Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma

Contact Info

Product

Resources

About